Expression of ARA55 mRNA in prostate carcinoma tissues and its significance.
- Author:
Nian-qin YANG
1
;
Run-sheng LI
;
Dong LI
;
Jian-jun SHA
;
Ping LI
;
Yi-xin WANG
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; genetics; LIM Domain Proteins; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostatic Neoplasms; genetics; pathology; therapy; RNA, Messenger; genetics; metabolism; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome
- From: National Journal of Andrology 2007;13(8):696-699
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the expression of ARA55 mRNA in the prostate carcinoma tissues and its clinical significance.
METHODSReal-time RT-PCR was used to examine the expression of ARA55 mRNA in the samples of the prostate carcinoma tissues from 32 patients.
RESULTSARA55 mRNA expressed in different degrees in all the samples. The Ct values were 20.57 +/- 0.20 and 16.33 +/- 0.31 at T1-T2 and T3-T4 stages, 23.13 +/- 0.13 and 17.3 +/- 0.19 for those with Gleason score < or =7 and >7, 24.70 +/- 0.27 and 17.21 +/- 0.34 for those with PSA < or =10 microg/L and >10 microg/L, and 23.82 +/- 0.21 and 16.71 +/- 0.32 for those that responded to endocrinological therapy and those that failed to, respectively. There was a significant difference between the former and the latter.
CONCLUSIONARA55 mRNA expression is significantly correlated with the clinical characteristics of the patient. And ARA55 can be regarded as a prognostic molecular marker for prostate carcinoma as well as a predictor of endocrinological therapeutic effect on the disease.
